arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Tango Therapeutics, Inc.

TNGX
$27.07 ▼ -1.92 (-6.62%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
26 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
23
Health
Poor
Bearish
auto_awesome

Analytical Summary

Tango Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.9B
Dividend Yield
Revenue Growth N/M
Op. Margin None
ROIC -12.5%
FCF / Share $-0.31
Trailing P/E
Price / Book 10.0x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

26-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-45.51M
↓ -14.1%
Operating Margin Operating profit as % of sales
26.2%
↑ +109.2% 1th
FCF / Share Free cash flow per share
$-0.31
↑ +18.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
23
Cash Quality
78

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters